2. Search Result
Search Result
Results for "

KIF5B

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-133551
    WF-47-JS03

    		RET Cancer
    WF-47-JS03 is a potent and selective RET kinase inhibitor with IC50s of 1.7 nM and 5.3 nM for KIF5B-RET transfected Ba/F3 cells and CCDC6-RET transfected LC-2/ad lung cancer cells, respectively. WF-47-JS03 demonstrates >500-fold selectivity against kinase insert domain receptor (KDR). Effective brain penetration .
    WF-47-JS03
  • HY-RS07290
    KIF5B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KIF5B Human Pre-designed siRNA Set A contains three designed siRNAs for KIF5B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KIF5B Human Pre-designed siRNA Set A
    KIF5B Human Pre-designed siRNA Set A
  • HY-RS24765
    Kif5b Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Kif5b Rat Pre-designed siRNA Set A contains three designed siRNAs for Kif5b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Kif5b Rat Pre-designed siRNA Set A
    Kif5b Rat Pre-designed siRNA Set A
  • HY-RS18287
    Kif5b Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Kif5b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kif5b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Kif5b Mouse Pre-designed siRNA Set A
    Kif5b Mouse Pre-designed siRNA Set A
  • HY-170852
    QZ2135

    		PROTACs RET Cancer
    QZ2135 (compound 20) is a RET-targeted PROTAC degrader with in vivo antitumor properties in a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The degradation activities of QZ2135 targeting KIF5B-RET have DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C), respectively. QZ2135 is composed of a target protein ligand (red part) RET ligand-3 (HY-170853), an E3 ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC Linker (black part) 7-Iodohept-1-yne (HY-W587352), in which the target protein ligand + linker form a conjugate RET Ligand-Linker Conjugate-1 (HY-170854) .
    QZ2135
  • HY-146710
    RET-IN-16

    		RET Cancer
    RET-IN-16 is a potent and selective RET inhibitor with IC50s of 3.98 nM, 8.42 nM, 15.05 nM, 7.86 nM, 5.43 nM and 8.86 nM for RET(WT), RET(M918T), RET(V804L), RET(V804M), RET-CCDC6 and RET-KIF5B, respectively. RET-IN-16 has anticancer effects .
    RET-IN-16
  • HY-170855A
    YW-N-7 TFA

    		PROTACs RET Cancer
    YW-N-7 (TFA) is a PROTAC that targets both the inhibition and degradation of RET kinase, with a DC50 of 88 nM. YW-N-7 (TFA) exhibits antitumor activity in a KIF5B-RET-driven xenograft mouse tumor model and can be used in the area of cancer (Structure: red part represents the target protein ligand: HY-170856; blue part represents the E3 ligase ligand: HY-1708557; black part represents the linker; E3 ligase ligand + linker: HY-170858) .
    YW-N-7 TFA
  • HY-178061
    APS03118

    		ERK RET Cancer
    APS03118 is an orally active, potent and selective rearranged during transfection (RET) inhibitor. APS03118 broadly inhibits RET fusions and mutations (including G810, V804, L730, and Y806 variants), with IC50 values predominantly below 1 nM (0.095 nM for WT; ranging from 0.00438 to 5.72 nM for mutants), and demonstrates marked superiority against RET G810 mutations. APS03118 inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), with >20-fold selectivity over most off-target kinases (except FLT3 and YES). APS03118 induces complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient derived xenografts (PDXs) and significantly prolongs survival in an intracranial CCDC6-RET metastasis mice model. APS03118 can be used for selective RET inhibitor (SRI)-resistant, RET-driven cancer research .
    APS03118

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: